enGene Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
enGene Therapeutics Inc. (ENGN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $1.46 per share for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-08.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-09-08
- enGene Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-01-31 was 6.90 CAD/shares, a 29.46% increase year-over-year.
- enGene Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-07-31 was 2.53 CAD/shares, a 60.34% decline year-over-year.
- enGene Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-04-30 was 3.23 CAD/shares, a 72.16% decline year-over-year.
- enGene Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-01-31 was 5.33 CAD/shares, a 1.84% decline year-over-year.
- enGene Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was 4.62 CAD/shares, a 36.71% decline from fiscal 2024.
- enGene Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was 7.30 CAD/shares, a 146.62% increase from fiscal 2023.
- enGene Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was 2.96 CAD/shares, a 260.98% increase from fiscal 2022.
- enGene Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was 0.82 CAD/shares.
CAD/shares
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2026-01-31 | 6.90 CAD/shares 10-Q · filed 2026-03-09 | ||||
| 2025-10-31 | 4.62 CAD/shares 10-K · filed 2025-12-22 | ||||
| 2025-07-31 | 2.53 CAD/shares 10-Q · filed 2025-09-11 | 4.59 CAD/shares 10-Q · filed 2025-09-11 | |||
| 2025-04-30 | 3.23 CAD/shares 10-Q · filed 2025-06-12 | 5.23 CAD/shares 10-Q · filed 2025-06-12 | |||
| 2025-01-31 | 5.33 CAD/shares 10-Q · filed 2026-03-09 | ||||
| 2024-10-31 | 7.30 CAD/shares 10-K · filed 2025-12-22 | ||||
| 2024-07-31 | 6.38 CAD/shares 10-Q · filed 2025-09-11 | 7.48 CAD/shares 10-Q · filed 2025-09-11 | |||
| 2024-04-30 | 11.60 CAD/shares 10-Q · filed 2025-06-12 | 8.87 CAD/shares 10-Q · filed 2025-06-12 | |||
| 2024-01-31 | 5.43 CAD/shares 10-Q · filed 2025-03-10 | ||||
| 2023-10-31 | 2.96 CAD/shares 10-K · filed 2024-12-19 | 3.90 CAD/shares 10-K · filed 2024-01-29 | |||
| 2022-10-31 | 0.82 CAD/shares 10-K · filed 2024-01-29 |
USD/shares
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month |
|---|---|---|---|
| 2026-07-31 | $1.46 10-Q · filed 2026-09-08 | $4.55 10-Q · filed 2026-09-08 | |
| 2026-04-30 | $0.00 10-Q · filed 2026-06-15 | $9.53 10-Q · filed 2026-06-15 | |
| 2025-07-31 | $2.53 10-Q · filed 2026-09-08 | $4.59 10-Q · filed 2026-09-08 | |
| 2025-04-30 | $3.23 10-Q · filed 2026-06-15 | $5.23 10-Q · filed 2026-06-15 | |
| 2024-07-31 | $6.38 10-Q · filed 2024-09-10 | $7.48 10-Q · filed 2024-09-10 | |
| 2024-04-30 | $11.60 10-Q · filed 2024-06-14 | $8.87 10-Q · filed 2024-06-14 | |
| 2024-01-31 | $5.43 10-Q · filed 2024-03-11 | ||
| 2023-07-31 | $0.56 10-Q · filed 2024-09-10 | $0.50 10-Q · filed 2024-09-10 | |
| 2023-04-30 | $1.50 10-Q · filed 2024-06-14 | $1.50 10-Q · filed 2024-06-14 | |
| 2023-01-31 | $0.00 10-Q · filed 2024-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |